Drug profile · INN
asfotase alfa
STRENSIQ
asfotase alfa (STRENSIQ) is a pyrophosphate hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
Drug details — asfotase alfa
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
asfotase alfa (STRENSIQ) is a pyrophosphate hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Pyrophosphate hydrolytic enzyme
Primary target: Pyrophosphate
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is asfotase alfa?
asfotase alfa (STRENSIQ) is a pyrophosphate hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for asfotase alfa?
STRENSIQ is a marketed brand name for asfotase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of asfotase alfa?
asfotase alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.